Donor risk index for African American liver transplant recipients with hepatitis C virus

Hepatology

Volumn 58, Issue 4, 2013, Pages 1263-1269

  Shores, Nathan J ^a   Dodge, Jennifer L ^b   Feng, Sandy ^b   Terrault, Norah A ^b  

^a TULANE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; COLD ISCHEMIA; DONOR; DONOR RISK INDEX; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884978231     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26478     Document Type: Article

References (32)

1. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008;134:1764-1776.
2. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-706.
3. Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, et al. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol 2008;6:1403-1411.
4. Saxena V, Lai JC, O'Leary JG, Verna EC, Brown RS Jr, Stravitz RT, et al. Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl 2011;18:524-531.
5. Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, et al. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation 2012;94:178-184.
6. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008;103:901-910.
7. Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007;39:3204-3206.
8. Smallwood GA, Coffey G, Davis L, Martinez E, Stieber AC, Heffron TG. Hepatitis C treatment outcomes of African Americans following liver transplantation. Transplant Proc 2002;34:3317-3318.
9. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271.
10. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
11. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
12. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
13. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transpl 2010;10:1003-1019.
14. Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl 2009;15:1126-1132.
15. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-2123.
16. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212.
17. 2010 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2010. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
18. Trotter JF, Wisniewski KA, Terrault NA, Everhart JE, Kinkhabwala M, Weinrieb RM, et al. Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007;46:1476-1484.
19. Maluf DG, Edwards EB, Stravitz RT, Kauffman HM. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl 2009;15:592-599.
20. Lai JC, Feng S, Roberts JP. An examination of liver offers to candidates on the liver transplant wait-list. Gastroenterology 2012;143:1261-1265.
21. Kamal A. Graft loss and racial mismatch in hepatitis C virus-positive liver transplant patients. Liver Transpl 2012;18:505-506.
22. Busch MP, Glynn SA, Stramer SL, Orland J, Murphy EL, Wright DJ, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006;46:469-475.
23. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
24. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-242.
25. Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006;42:82-91.
26. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010;51:1168-1175.
27. Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, et al. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009;6:46.
28. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-935.
29. Harris RA, Sugimoto K, Kaplan DE, Ikeda F, Kamoun M, Chang KM. Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 2008;48:70-79.
30. Graziadei IW, Vogel W. Treatment of patients infected with chronic hepatitis C genotype 2 and 3: more data, more questions? Hepatology 2009;49:345-347.
31. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012;94:197-203.
32. Biggins SW, Trotter J, Gralla J, Burton JR Jr, Bambha KM, Dodge J, et al. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 2013;58:969-976.